$GRAIL(GRAL.US) | Goldman Sachs ๐ข๐ง๐ข๐ญ๐ข๐๐ญ๐๐ฌ ๐๐จ๐ฏ๐๐ซ๐๐ ๐ on ๐๐๐๐๐ with a ๐๐๐ฎ๐ญ๐ซ๐๐ฅ rating and a ๐ฉ๐ซ๐ข๐๐ ๐ญ๐๐ซ๐ ๐๐ญ ๐จ๐ $๐๐
Analyst sees GRAL's path to profitability hinging on uncertain FDA approval and CMS coverage for its Galleri multi-cancer early detection test.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments